Adjuvant therapy of pancreatic cancer.
Adjuvant therapy for pancreatic cancer remains controversial. However, both sides of the Atlantic Ocean agree that at least gemcitabine should be the pivotal agent offered to all patients. The role of radiation therapy remains somewhat inconclusive but chemoradiation, whether in the neoadjuvant or adjuvant setting is a standard option often utilized in the USA. This review is an update from the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, USA. We present the summary of the findings from Abstracts #4020, #4021, #4040 and #4049 and discuss the impact on this group of patients.
Division of Hematology and Oncology, Department of Radiation Oncology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA. cchaulagain@tuftsmedicalcenter.org
Chakra P
CP
Chaulagain
John
J
Ng
David
D
Wazer
Muhammad Wasif
MW
Saif
D006801:Humans; D007167:Immunotherapy; D020360:Neoadjuvant Therapy; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D061766:Proton Therapy; D018631:ras Proteins / Q000235:genetics
C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins